Capsular Contracture Treatments
Closed Capsulotomy (non-surgical)
In this non-surgical procedure, the surgeon forcibly squeezes the implant, in hopes of "popping" the scar tissue (opening it up). Breast implant manufacturers do not recommend this, as it can lead to possible rupture of the implant. Implants that are ruptured due to closed capsulotomy are not covered under the warranty (this includes Mentor and Allergan). You are awake for this, and receive no local anesthesia. And yes, it can be painful, but thankfully, it only lasts a few seconds, and then it's over.
This procedure is usually not recommended, since it has a very low success rate, and again, puts you at risk for breast implant rupture.
Open Capsulotomy (surgical)
In this procedure, the surgeon goes into the pocket and "scores", or cuts, the scar tissue, in order to release the capsule's hold on the implant. The scar tissue is not removed. Depending on the surgeon and his skill/experience, it's possible to do this procedure via the transaxillary incision, as well as via the crease and areola incisions. You will be given a local anesthetic with IV sedation, or general anesthesia for this particular procedure.
Open Capsulectomy (surgical)
T his is the most successful treatment for capsule contracture. In this procedure, the surgeon goes in and actually removes the scar capsule. This is a lengthier surgery, but is well worth it, especially when it's successful. Once the capsule is removed, your body will form a new capsule around the breast implant.
Medicines, Vitamins, and Supplements for Capsular Contracture Treatment
Some surgeons believe that Papaverine (also known as Papacon, Para-Time S. R., Pavabid Plateau, Pavacot, and Pavagen) may help to stop the progression of capsular contracture. Pavabid is in a class of drugs called vasodilators. It relaxes veins and arteries, which makes them wider and allows blood to pass through them more easily. Papaverine is also a smooth muscle relaxant. The target of Papaverine, when used to treat capsule contracture, is the smooth muscle-like fibers in contractile scars. The flip side is that some doctors do not believe that it helps at all. There is no evidence that this drug will stop and/or reverse the effects of capsule contracture.
Scar tissue consists of collagen strands. Taking vitamin E is thought
to soften these strands, thus making the capsule
softer and more pliable. Unfortunately,
there is no evidence that vitamin E really works
in treating or preventing capsular contracture.
Some plastic surgeons use antibiotics to treat capsular contracture, though this isn't always successful. In the event that a person has capsular contracture, and the breast begins to swell, and/or become sore or painful, antibiotics may help. However, simply giving someone antibiotics in hopes of reversing a well-formed capsule isn't likely to be successful.
Accolate (asthma medication)
Accolate, a drug used in the treatment of Asthma, is the newest treatment for capsule contracture. It is used due to it's anti-inflammatory properties. It is a leukotriene receptor inhibitor. Leukotrienes are a group of chemical compounds that occur naturally in white blood cells (also known as leukocytes). They're able to produce allergic and inflammatory reactions. This drug inhibits this process. Accolate is said to work best on early contractures, but may reverse existing capsules. If the capsule is well-formed, it can take several months to successfully treat it. Prophylactic treatment may be used in women who are at a higher risk for capsule contracture, such as those who have had it previously.
Clinical studies still need to be done regarding the use of Accolate as a form of treatment for capsule contracture, although it does seem to have helped many women.
Using Accolate or other asthma medications to
treat capsule contracture is "off-label" use, as
these drugs haven't been approved by the FDA for
treatment of capsular contracture.
External ultrasound, according to some
doctors, helps capsule contracture. It may
possibly reduce swelling, help to regulate
inflammation, and facilitate healing, thus
reducing the risk of recurrence. Ultrasound is
usually accepted by patients, as it is easy to
perform, and free of any major complications.
Prophylactic ultrasound treatment may be used as
"In many cases, the patients and surgeon noted a very significant softening and improved appearance of the breast following treatment with Accolate for a period of one to three months", says Dr. Schlesinger. "For some women who otherwise would have needed surgical correction of their contracture, surgery was no longer necessary."
Dr. Schlesinger says that he has been using Accolate "for approximately three years and has found it most affective in treating early-phase contracture (less than six months) and as a preventative treatment in patients considered "high risk" for contracture; this group includes those with a history of previous capsular contracture and patients with a tendency toward hypertropic scarring. However, he says there has also been some success in using the drug to treat established contracture.
"Our preliminary findings do not suggest that Accolate is the answer for every patient with contracture," advises Dr. Schlesinger. "For some patients whose capsular contracture is severe and long-standing, meaning a year or more, surgical intervention is still the best option. But for patients who are not good candidates for surgery or elect not to undergo surgery - such as breast reconstruction patients who may have experienced capsular contracture following radiation therapy - it may be possible to achieve some degree of improvement using Accolate." Dr. Schlesinger's results are based on a treatment of 20 milligrams of Accolate administered twice daily - the same dosage indicated for the preventative and chronic treatment of asthma in adults and children 12 years of age or older. From November 1996 through 1998, Accolate tablets were prescribed more than 4 million times for asthma treatment, and reportedly, the drug is well tolerated. Side effects may include headache (12.9%) and nausea (3.1%).
"Dr. Schlesinger's clinical experience with Accolate is very preliminary, but is consistent with other research suggesting that certain medications may be useful in helping to prevent or improve the symptoms of capsular contracture in properly selected patients," says James Baker, Jr,. MD, Breast Surgery Committee chair for the American Society for Aesthetic Plastic Surgery.
Article by Dr. S. Larry Schlesinger, MD.
The Effect of Zafirlukast (Accolate) on Early Capsular Contracture in the Primary Augmentation Patient: A Pilot Study
Russell R. Reid, M.D. PhD, Susan D. Greve, MS RN, and Laurie A. Casas, M.D. F.A.C.S.
Division of Plastic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL
and Evanston Northwestern Healthcare, Glenview, IL
Introduction: Significant capsular contracture (Baker Class III or IV), occurring at a rate of 4.6-25% in submuscular saline breast augmentation1, presents a formidable challenge to the plastic surgeon. Certainly, the recent use of the leukotriene antagonist zafirlukast (Accolate; AstraZeneca, Wayne, PA) for contracture reversal has received much attention in the popular media. However, validation of its effectiveness rests only on limited case series and anecdotal reports2,3. To this end, a single surgeon's experience using Accolate in the treatment of capsular contracture in primary, submuscular augmentation with saline smooth ?walled implants is presented.
Methods: From the period of December 2001 to January 2003, the senior author performed 37 bilateral submuscular augmentation mammaplasties with saline smooth-walled breast implants (74 breasts). All patients were placed on the same postoperative protocol, which included early implant mobility (massaging) and vitamin E 400 I.U. orally twice daily at 4 weeks. A prospective analysis of the effects of Accolate on early capsular contracture was carried out in the following manner. Patients were regularly evaluated in the office by the operating and clinical staff (2 independent observers) and rated for capsular contracture using a modification of the Baker classification4. We define contracture as follows: Class 1=breast absolutely natural, augmentation undetectable; Class 1.5=breast soft, but implant is detectable by physical examination; Class 2=mild firmness, prosthesis not detectable by examiner or patient; Class 2.5= mild firmness and implant detectable by examiner but not patient; Class 3=breast moderately firm and detectable by patient; Class 4=severe firmness, obvious from observation, with pain. Patients who demonstrated any capsular contracture (>=1.5) were given Accolate 20mg orally twice daily and assessed at 3- and 6-month time-points for any change in contracture. The endpoint of this study was 6 months or a return to a Class 1 capsular score. One patient failed to complete the study.
Results: Using our modification, 33 of the total 74 breasts had no capsular contracture and thus were rated Class 1 (45%). 41 breasts (55.0%) were found to have early, mild capsular contracture (Class 1.5 or greater). Of these 41 breasts, 29 mildly contracted breasts have completed the protocol: 12 breasts were scored as 1.5, 15 breasts as 2, 1 breast as class 2.5 and 1 breast as class 3. Responses were scored as either complete (return to class 1), partial (reduction in capsular contracture index by 0.5), or nil (modified Baker class the same or worse despite therapy). Mean follow-up was 6.3 months. After an average of 4.8 months of treatment, 16 out of 29 breasts (55.2%) demonstrated a complete response to Accolate therapy, whereas 7 of 29 (24.1%) demonstrated a partial response to the leukotriene antagonist. The remaining 6 of 29 (20.7%) had no response to therapy, either staying the same grade or worsening. Therefore, a positive response (complete or partial) was seen in a statistically significant proportion of treated breasts (79.3%, p<0.05).
Conclusions: Our initial results support the effectiveness of Accolate in early capsular contracture after submuscular saline smooth augmentation mammaplasty. Further follow-up will demonstrate its long-term effects.
1) Mentor Corporation. Saline Prosthesis: 2002 Product Insert.
2) Sclesinger SL, Ellenbogen R, Desvigne MN, Svehlak S, and Heck R. Zafirlukast (Accolate): A new treatment for capsular contracture. Aesthetic Surg. J. 2002; 22: 329-336.
3) Schlesinger SL and Heck RT. A new treatment for capsular contracture. (Letter to the editor). Aesthetic Surg. J. 2002; 21: 164-165.
4) Spear SL and Baker Jr., JL. Classification of capsular contracture after prosthetic breast reconstruction. Plast. Reconstr. Surg. 1995; 96: 1119-1124.